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Abstract
Background: MFSD2A (major facilitator superfamily domain containing 2) gene maps on chromosome 1p34 within
a linkage disequilibrium block containing genetic elements associated with progression of lung cancer.
Results: Here we show that MFSD2A expression is strongly downregulated in non-small cell lung cancer cell lines
of different histotypes and in primary lung adenocarcinomas. Experimental modulation of MFSD2A in lung cancer
cells is associated with alteration of mRNA levels of genes involved in cell cycle control and interaction with the
extracellular matrix. Exogenous expression of MFSD2A in lung cancer cells induced a G1 block, impaired adhesion
and migration in vitro, and significantly reduced tumor colony number in vitro (4- to 27-fold, P < 0.0001) and
tumor volume in vivo (~3-fold, P < 0.0001). siRNA knockdown studies in normal human bronchial epithelial cells
confirmed the role of MFSD2A in G1 regulation.
Conclusion: Together these data suggest that MFSD2A is a novel lung cancer tumor suppressor gene that
regulates cell cycle progression and matrix attachment.
Background
Cancer progression is defined as the stepwise process
t h r o u g hw h i c hc e l l se v o l v et o w a r d sam o r em a l i g n a n t
and aggressive phenotype [1]. This process results from
the accumulation of somatic genetic and epigenetic
changes occurring within neoplastic cells [2]. However,
a growing body of evidence also points to the role of
genetic background in cancer susceptibility, progression,
and prognosis [3-5]. We previously identified a 106 kb
linkage disequilibrium block containing genetic elements
associated with survival in lung adenocarcinoma
(ADCA) patients [6]. The refined region maps to chro-
mosome 1p34 and includes MYCL1, TRIT1 (tRNA iso-
pentenyltransferase 1), and MFSD2A (major facilitator
superfamily domain containing 2). While the role of
MYCL1 and TRIT1 in lung tumor growth and develop-
ment has been studied [6,7], no information is available
o nM F S D 2 A .T h u s ,w ea d d r e s s e dt h ef u n c t i o n a lr o l eo f
MFSD2A in lung tumorigenesis.
Results
Downregulation of MFSD2A in lung cancer
Based on our previous finding of MFSD2A downregula-
tion in a pool of lung tumor specimens [7], we extended
the analysis to 18 individual samples of lung ADCA
tumors and corresponding benign adjacent tissue.
MFSD2A mRNA levels were strongly downregulated
(2- to 80-fold) in 17/18 tumors with an overall 5-fold
decrease in ADCA as compared to normal lung speci-
mens (P = 5.1e-05) (Fig. 1A). Statistical analysis showed
no association with sex, age at diagnosis, or clinical
stage (data not shown). It was not possible to evaluate
association with smoking status since 17/18 patients
were smokers.
Measurement of MFSD2A mRNA levels in NSCLC
cell lines and normal human bronchial epithelial cell
(HBEC) lines (Additional file 1), normalizing the data to
the average expression of HBECs, revealed downregula-
tion of MFSD2A (2- to 44-fold) in 33/47 (70%) NSCLC
cell lines but only in 4/20 (20%) HBEC lines (Fig. 1B).
To identify the lung cell types expressing MFSD2A
protein, we have assayed by immunohistochemistry spe-
cimens of normal lung tissue and lung ADCA. Using
non-transfected cells as a negative control (Fig. 2A), we
* Correspondence: Tommaso.dragani@istitutotumori.mi.it
1Department of Predictive and for Prevention Medicine, Fondazione IRCCS
Istituto Nazionale Tumori, Milan, Italy
Spinola et al. Molecular Cancer 2010, 9:62
http://www.molecular-cancer.com/content/9/1/62
© 2010 Spinola et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.confirmed the specificity of MFSD2A antibody on trans-
fected cells over-expressing MFSD2A (Fig. 2B). In nor-
mal lung tissue, immunostaining of MFSD2A was
observed in epithelial cells (Fig. 2C), whereas lung
ADCAs showed no detectable MFSD2A protein levels
(Fig. 2D) in agreement with the data of mRNA
expression.
A specific transcriptional profile is associated with
MFSD2A over-expression
Changes in gene expression dependent on or correlated
to MFSD2A were studied using two different approaches
both based on microarray analysis.
Class comparison analysis of the expression profile of
lung tumor cells transiently transfected with MFSD2A
identified 460 genes whose expression differed signifi-
cantly after MFSD2A exogenous expression (P <0 . 0 0 1 ,
FDR < 0.03) (Additional file 2). Microarray results were
validated on a subset of 15 genes by real-time PCR
(rho = 0.83, P < 0.0001). Analysis with the DAVID
(Database for Annotation, Visualization and Integrated
Discovery) Functional Annotation Tool [8] pointed to
four main gene ontology categories: regulation of tran-
scription, mitosis, apoptosis, and cell cycle.
Comparison of microarray data for NSCLC cell lines
showing the highest and lowest MFSD2A mRNA levels
Figure 1 MFSD2A expression is downregulated in human lung primary tumors and lung cancer cell lines. (A) MFSD2A expression in 18
paired normal and tumor specimens obtained from lung adenocarcinoma patients. (B) MFSD2A expression in 20 human bronchial epithelial cell
(HBEC) and 47 non small cell lung cancer (NSCLC) cell lines. Box boundaries indicate the 25th and 75th percentile, line within each box indicates
the median, and error bars indicate the 10
th and 90
th percentile.
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ence (P < 0.005; Additional file 3). Most of the
MFSD2A-correlated genes control developmental pro-
cesses, neurodevelopment, cell motility, and adhesion.
MFSD2A controls tumor growth and G0/G1 phase of
lung cells
NSCLC cell lines A549 (lung carcinoma), NCI-H520
(squamous cell carcinoma), and NCI-H596 (adenosqua-
mous carcinoma), expressing MFSD2A at very low
levels, were stably transfected to over-express MFSD2A
(Fig. 3A) and showed a 4-, 16-, and 27-fold reduction in
colony number in a colony formation assay, respectively,
as compared to their empty vector-transfected counter-
parts (P < 0.0001) (Fig. 3B).
Analysis of tumor growth in nude mice injected sub-
cutaneously with control or MFSD2A-transfected
A549 cells revealed xenograft tumors at 2 weeks after
injection in all control cell-treated mice, whereas tumors
were measurable in all mice treated with MFSD2A-
transfected cells only at 5 weeks post-injection. At the
end of the observation period, tumors grown from
MFSD2A-expressing cells were, on average, ~3-fold
smaller than those from control cells (P < 0.0001)
(Fig. 3C).
FACS analysis of A549 cells stably expressing
MFSD2A showed a significant increase in the G1 phase
fraction and a reduction in DNA synthetic activity in
S phase (Fig. 4, left panel). Analysis of three replica
experiments showed that the proportion of cells accu-
mulating at the G1 peak increased from 33% to 47% in
MFSD2A-over-expressing cells, whereas the proportion
of cells in S phase decreased from 18% to 13%.
To confirm this finding we studied changes in the cell
cycle profile of normal human bronchial epithelial cells
(HBECs) transfected with siRNAs targeting MFSD2A.
Figure 2 Immunohistochemical analysis of MFSD2A protein. No MFSD2A protein was detected in empty vector-transfected HEK-293T cells
(negative control) (panel A), whereas a clear and mainly cytoplasmic staining pattern was observed in MFSD2A-transfected cells (panel B). In
normal lung tissue, immunoreactivity is detected in lung alveolar cells (panel C), whereas almost no detectable staining is observed in lung
ADCA (panel D).
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(5’-catggagagtaacctcatcat-3’,5 ’-gagtgtcactgggcatttcta-3’,
5’-ccactgtgaatatgccaagga-3’) induced >3-fold reduction in
MFSD2A mRNA levels. Low MFSD2A expression
resulted in fewer cells accumulated in G1 as compared to
control cells (from 59% to 41%) (Fig. 4, right panel),
whereas distribution of cells in S and G2/M phases varied
among the different samples (three independent repli-
cates). Overall statistical analysis showed a significant
effect of MFSD2A category of expression (over-expres-
sion or silencing) on modulation of cells accumulating in
G1 fraction (P < 0.0001), with significant differences
between the two cell lines (P = 0.003), and no significant
interaction between MFSD2A expression and cell lines.
MFSD2A over-expression modulates cell adhesion and
cell migration
Adhesion and migration of stably transfected A549 cells
were tested on membranes coated with different extra-
cellular matrix (ECM) substrates (collagen I, collagen
IV, and fibronectin) as compared to BSA-coated nega-
tive control membranes. Adhesion of MFSD2A-over-
expressing cells was reduced by ~15% on collagen I, by
~40% on collagen IV, and by ~70% on fibronectin-
coated membranes (Fig. 5A). Statistical analysis indi-
cated a significant gene and substrate effect as well as a
significant gene-substrate interaction (P < 0.0001).
The effects of MFSD2A expression on cancer cell
migration were evaluated in a time-course experiment
with the same ECM substrates used in the adhesion
assay. No difference was seen in migration on collagen
I-coated membranes, which also displayed the smallest
effects in adhesion experiments (not shown). In contrast,
the different migratory behavior of MFSD2A-transfected
cells on collagen IV- and fibronectin-coated membranes
was already apparent at early time points and was main-
tained throughout the whole experiment (Fig. 5B). At
the final time point of the experiment, migration was
reduced by ~60% on collagen IV and by ~80% on fibro-
nectin. Statistical analysis indicated a significant
Figure 4 MFSD2A affects G1 phase of lung tumor and normal cells.C e l lc y c l ep r o f i l eo fA 5 4 9c e l l so ver-expressing MFSD2A (A) and of
normal HBECs after MFSD2A silencing (B).
Figure 3 Exogenous expression of MSFD2 inhibits growth of NSCLC cell lines in vitro and in vivo. (A) Western blots showing MFSD2A
expression in MFSD2A-transfected and empty vector-transfected cell lines. (B) Colony number in each cell lines tested by colony formation
assay. Data are given as mean ± SE of 6 independent replicas. (C) In vivo growth of MFSD2A-transfected and control (empty vector-transfected)
A549 cells. Data are given as mean ( ± SE) tumor volume in 5 mice (control) or from two groups of 5 mice each injected with two independent
MFSD2A clones.
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0.0001) as well as between substrates (collagen-IV and
fibronectin) (P < 0.001).
To characterize the genes responsible for modulation
of cell adhesion and cell migration, we have measured
the transcript levels of genes involved in extracellular
matrix structure and remodeling. Analysis of two inde-
pendent A549 cell clones stably transfected with
MFSD2A showed that 41 of 66 informative gene targets
were downregulated (P < 0.05) as compared to A549
control cells and 25 of these genes showed a >3-fold
change (Table 1).
Table 1 List of extracellular matrix genes >3-fold downregulated by MFSD2A over-expression in stable-transfected
A549 cells
Gene symbol Gene name Fold-change* P
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 0.25 1.13E-07
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 0.07 2.57E-02
COL11A1 collagen, type XI, alpha 1 0.10 2.60E-02
COL12A1 collagen, type XII, alpha 1 0.09 1.01E-03
COL4A2 collagen, type IV, alpha 2 0.25 1.78E-07
COL5A1 collagen, type V, alpha 1 0.25 1.22E-07
COL6A1 collagen, type VI, alpha 1 0.18 4.30E-03
COL7A1 collagen, type VII, alpha 1 0.25 3.60E-07
CTGF connective tissue growth factor 0.07 1.56E-08
CTNND1 catenin (cadherin-associated protein), delta 1 0.32 1.05E-02
FN1 fibronectin 1 0.16 2.53E-02
ICAM1 intercellular adhesion molecule 1 0.25 2.18E-07
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 0.18 3.52E-03
ITGA7 integrin, alpha 7 0.19 3.96E-03
LAMB3 laminin, beta 3 0.15 2.46E-02
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 0.33 7.35E-03
MMP10 matrix metallopeptidase 10 (stromelysin 2) 0.27 1.84E-02
MMP14 matrix metallopeptidase 14 (membrane-inserted) 0.16 2.17E-03
MMP15 matrix metallopeptidase 15 (membrane-inserted) 0.25 3.21E-02
SELL selectin L 0.19 4.59E-03
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 0.08 1.08E-02
TGFBI transforming growth factor, beta-induced, 68 kDa 0.25 3.22E-08
THBS1 thrombospondin 1 0.19 3.82E-03
THBS3 thrombospondin 3 0.31 9.78E-03
TIMP3 TIMP metallopeptidase inhibitor 3 0.02 6.21E-05
*With respect to untransfected A549 cells.
Figure 5 A549 cells stably expressing MFSD2A have reduced adhesive and migratory properties. (A) Adhesion of MFSD2A-expressing and
control A549 cells on membranes coated with different substrates. Data are given as mean ± SE in 2 independent experiments, with 8 replicas
in each experiment. (B) Migration of control and MFSD2A-expressing cells. Data are given as mean ± SE in 2 independent experiments, with 8
replicas in each experiment.
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>In this study, most of the primary lung tumors and
NSCLC cell lines examined showed significantly lower
MFSD2A expression as compared to their normal coun-
terparts. The mechanisms underlying the inhibition of
MFSD2A expression are unclear, although our prelimin-
ary experiments indicating restoration of MFSD2A
expression in NSCLC cell lines upon treatment with
5’-azacytidine, a methyltransferase inhibitor and
demethylating agent, suggest a role for methylation.
Other possible mechanisms of gene inactivation, such as
the presence of somatic mutations or the influence of
microRNAs, remain to be investigated.
Over-expression of MFSD2A in transfected lung cancer
cell lines was associated with reduced clonogenicity
in vitro and diminished tumorigenicity in vivo, an effect
due likely to the ability of MFSD2A to block the cell
cycle in the G1 phase and to impair adhesive and migra-
tory properties. Indeed, microarray data indicated that
MFSD2A regulates expression of genes controlling cell
cycle progression and correlates with expression of genes
affecting adhesion and motility. Although microarray
analysis also pointed to regulation of apoptotic genes, the
FACS profile of MFSD2A-transfected cells revealed no
increase in the sub-G1 phase fraction, no change was
observed after annexin V staining, and neither PARP nor
caspase cleavage was detected (data not shown).
MFSD2A has recently been described as the human
receptor for syncytin-2, a retrovirus-derived protein med-
iating fusion of placental trophoblasts; however, in silico
analysis predicts that the primary function of the gene is
in transport of carbohydrates [9]. The presence of this
gene within the MYCL1 linkage disequilibrium block asso-
ciated with differences in the survival of lung cancer
patients [6] suggests a role for MFSD2A in controlling
predisposition to lung cancer progression, although
sequencing of coding regions identified no functional poly-
morphism in MFSD2A that could account for this effect
[6]. Studies addressing the possible existence of genetic
variations in the promoter region and their role in popula-
tions of different ethnicities will shed light on the potential
role of MFSD2A in modifying lung cancer progression.
Conclusion
Based on the present findings we can conclude that
MFSD2A is a novel suppressor gene in lung cancer act-
ing on tumor growth and development through control
of cell cycle profile, matrix attachment, and cell motility.
Methods
Lung Primary Samples and Cell lines
Matched specimens of normal lung parenchyma and
lung adenocarcinoma tissue were obtained from patients
who underwent lobectomy at Istituto Nazionale Tumori
(Milan, Italy). Normal human bronchial epithelial cells
(HBECs) and lung tumor cell lines were available at the
tissue culture repository of the Hamon Center for Ther-
apeutic Oncology Research, UTSW Medical Center
(Dallas, TX) [10]. Cell lines that have been used are
listed in Additional file 1.
Quantitative real-time PCR
Total RNA was extracted with the RNeasy Midi kit
(Qiagen, Valencia, CA) and reverse-transcribed with
either the SuperScript First-Strand Synthesis System
(Invitrogen, Carlsbad, CA). MFSD2A mRNA expression
was analyzed using TaqMan gene expression assays
(Applied Biosystems, Foster City, CA): MFSD2A
(Hs00293017_m1), HPRT1 (Hs99999909_m1), and
GAPDH (4352934E).
Intron-spanning primers were designed to validate
microarray results of NCI-H520 transfected cells for the
following genes: DDIT3, DNAJB9, ELMO3, HRK, IRF1,
LAMP3, MX1, NUPR1, PARL, PPP1R15A, RYR1, S100P,
TCTA, UHMK1, WIPI1, and HPRT1 (housekeeping con-
trol). Amplification mixtures contained cDNA template,
Power SYBR® Green PCR Master Mix (Applied Biosys-
tems), and gene-specific PCR primers (sequences of oli-
gonucleotide primers are available upon request).
For the expression levels analysis of genes involved in
cell adhesion and cell migration pathways, we have used
the TaqMan Array Human Extracellular Matrix &
Adhesion Molecules 96-well plate (Applied Biosystems),
according to the manufacturer’s instructions.
Relative expression values were calculated using the
comparative Ct method.
Microarray analysis
Gene expression profile of NCI-H520 cells transfected
with recombinant MFSD2A or empty control vector (4
replicas/each) was analyzed using the Human-8 v3
Expression BeadChips (Illumina Inc., San Diego, CA,
USA). Intensity values of each hybridization were qual-
ity-checked and the data set was normalized using a
cubic spline algorithm, with BeadStudio Version 3 soft-
ware. A P-value < 0.05 was set as a cutoff to filter reli-
ably detected genes.
Gene expression profile of the 47 NSCLC cell lines
was analyzed on the Affymetrix GeneChips HG-U133A
and HG-U133B (together 44,928 elements; 23,583
unique genes) according to the manufacturer’s protocol.
Intensity values were quality-checked and the data set
was quantile-normalized.
MFSD2A over-expression and silencing
MFSD2A full-length transcript (NM_032793) was ampli-
fied from a pool of human lung cDNAs (primers
5’-ggtcatggccaaaggagaa-3’ and 5’-gaggatgctagccagctctgtg-3’),
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sequenced. Cell lines were transiently transfected using
FuGENE HD Transfection Reagent (Roche, Basel, Swit-
zerland). Stable transfectant clones were obtained after
selection with 5 (A549) or 2 (NCI-H596, NCI-H520)
μg/ml of blasticidin (Invitrogen) for 2 weeks.
siRNAs targeted against MFSD2A (5’-gcttcacaaagtgc-
caaccat-3’,5 ’-catggagagtaacctcatcat-3’,5 ’-gagtgtcact-
gggcatttcta-3’,5 ’-cacggcccatacatcaaactt-3’,5 ’-ccactgtga-
atatgccaagga-3’) were purchased from Qiagen. HBECs
cells, which express endogenous MFSD2A, were trans-
fected with 25 nM siRNA oligonucleotides using Oligo-
fectamine (Invitrogen) and harvested after 96 hours for
quantitative real-time PCR or cell cycle analysis.
Western blots and immunohistochemistry
MFSD2A expression in stably transfected cells was
detected by Western blottingw i t ha n t i - V 5 - H R Pa n t i -
body (Invitrogen).
Samples of paraffin-embedded sections of MFSD2A-
or empty vector-transfected HEK-293T cells, lung
ADCA tissue, and surrounding normal lung tissue were
used to prepare histological sections that were immu-
nostained using standard methods after antigen retrieval
performed in 0.07 M citrate buffer (pH = 6) at 95°C for
10 min. Mouse polyclonal anti-MFSD2A antibody
(H00084879-B01P; Abnova, Taipei City, Taiwan) was
used at a 1:170 dilution. Immunoreactive signals were
detected with ChemMate DAB (Dako, Glostrup,
Denmark).
In vitro assays
Colony formation assay was carried out in stably trans-
fected A549, NCI-H520, and NCI-H596 cells (6 repli-
cas). After 2 weeks of selection, colonies were methanol-
fixed, stained with 10% Giemsa, and manually counted.
Cell adhesion was measured using CAFCA (Centrifu-
gal Assay for Fluorescence based Cell Adhesion) assay
[11]. Briefly, six well strips were coated with different
substrates from Becton-Dickinson (Falcon, Milan, Italy).
Cells were labeled with the vital fluorochrome calcein
AM (Invitrogen) for 15 minutes at 37°C and aliquoted
into the bottom CAFCA miniplates, which were centri-
fuged to synchronize the contact of the cells with the
substrate. The miniplates were incubated for 20 minutes
at 37°C and mounted together with a similar CAFCA
miniplate to create communicating chambers for reverse
centrifugation. The relative number of cells bound to
the substrate (i.e. remaining in the wells of the bottom
miniplates) and cells that failed to bind to the substrate
(i.e. remaining in the wells of the top miniplates) was
estimated by top/bottom fluorescence detection with
GENios Plus microplate fluorometer (TECAN, Italy).
Percentage of adherent cells was determined 8 hours
after plating.
Cell migration in response to extracellular matrix sub-
strates was assessed by FATIMA (Fluorescence-Assisted
Transmigration Invasion and Motility) assay as
described [11]. Briefly, membranes of HTS Fluoro-
BlokTM transwell inserts with 8 μm pores (Becton-
Dickinson, Falcon) were coated on the underside with
v a r i o u sE C Mm o l e c u l e sa t4 ° Ca n db l o c k e dw i t h1 %
BSA. Cells were fluorescently tagged with 5 μg/ml DiI
lipophilic dye (Invitrogen) and plated in the upper
chamber. Migration was monitored at every hour by
independent fluorescence detection from the top (corre-
sponding to non-transmigrated cells) and bottom (corre-
sponding to transmigrated cells) side of the membrane
with GENios Plus microplate fluorometer (TECAN).
Cell cycle analysis of stably transfected cells was per-
formed on a FACScan (BD Biosciences, San Jose, CA) or
FACSCalibur flow cytometer (BD Biosciences). MFSD2A-
or empty vector-transfected cells were harvested and fixed
in 70% EtOH over night at 4°C. Cells were then incubated
in 500 μl of buffered propidium iodide (PI) staining solu-
tion containing 0.05% Triton X-100 (Sigma-Aldrich), 0.1
mg/ml RNase A (Millipore), and 50 g/ml PI (Sigma-
Aldrich) in PBS for 30 min at 37°C. Cells were briefly spun
down and resuspended in PBS. Flow cytometry data were
analyzed using FlowJo software (TreeStar, Ashland, OR)
with the aid of the Watson modeling algorithm.
In vivo tumor growth assay
Adult female CD-1 nude mice (purchased from Charles
River, Calco, Italy) were injected subcutaneously with 4 ×
10
6 A549 control or MFSD2A-transfected cells (2 indepen-
dent clones). Tumor size was measured weekly by calipers
and animals were sacrificed 8 weeks after injection.
Statistical analysis
Genes differentially expressed in the two classes of
either vector- or MFSD2A-transfected cells were identi-
fied using random variance t-statistics [12]. Microarray
data were analyzed using BRB ArrayTools developed by
Dr. Richard Simon and Amy Peng Lam http://linus.nci.
nih.gov/BRB-ArrayTools.html (Illumina experiment) or
using in-house Visual Basic software MATRIX 1.4 and
the Bioconductor R package affy (Affymetrix experi-
ment). Functional annotation in gene ontology (GO)
categories was carried out with the DAVID Functional
Annotation Tools [8]. Differences in quantitative mea-
sures were assessed by analysis of variance. Correlations
between expression levels were expressed by the Spear-
man’s correlation coefficient. Cell cycle parameters by
MFSD2A categories of expression (high, low) were ana-
lyzed using the generalized linear model, family = quasi-
binomial, procedure.
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Page 7 of 8Additional file 1: List of human lung cell lines that have been used.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-62-
S1.DOC]
Additional file 2: List of genes differentially expressed between
MFSD2A- and vector-transfected NCI-H520 cells. The gene expression
profile of NSCLC line NCI-H520 transiently transfected cells (4 replicas)
was analyzed using the Human-8 v3 Expression BeadChips (Illumina Inc.,
San Diego, CA). The data set was normalized using a cubic spline
algorithm, with BeadStudio Version 3 software. A P-value < 0.05 was set
as a cutoff to filter reliably detected genes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-62-
S2.DOC]
Additional file 3: List of genes differentially expressed between
lung cancer cell lines by MFSD2A mRNA levels. The gene expression
profile of 47 NSCLC cell lines was analyzed on the Affymetrix GeneChips
HG-U133A and HG-U133B. Arrays from both types were pooled and
normalized to their 100 common control genes. Groups of samples were
compared by calculating log2 ratios for each gene. A T-test P-value <
0.005 was set as a cutoff to select differentially expressed genes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-62-
S3.DOC]
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